Shares of Aethlon Medical, Inc. (Nasdaq: AEMD) surged more than 471% during Thursday's premarket session on September 17, 2026, following the disclosure of a definitive merger agreement with North Immunology, a private biotechnology firm.

Key Points

• AEMD shares rocketed more than 471% in premarket trading on September 17, 2026, after the merger announcement.
• The all-stock transaction will create a newly formed Nasdaq-listed entity named North Immunology, Inc., which will trade under the ticker symbol NRTX.
• North Immunology shareholders and private placement participants will control approximately 95% of the combined enterprise, while Aethlon stockholders will retain about 4.75%.
• A concurrent $180 million private placement is supported by prominent healthcare investors such as Bain Capital Life Sciences and Janus Henderson, providing funding runway through late 2028.
• The company's flagship therapeutic candidate, NOR-101, a bispecific antibody targeting atopic dermatitis, is scheduled to begin Phase 1a clinical trials in early 2027.

Deal Structure and Ownership

The transaction, publicly disclosed on September 17, 2026, will be executed through two wholly owned merger subsidiaries, Nighthawk Merger Sub Corp. and Nighthawk Second Merger Sub, LLC. Once completed, the combined organization will operate under the name North Immunology, Inc. and will maintain its listing on the Nasdaq Capital Market under the ticker symbol NRTX.

Under the merger agreement, North Immunology's existing shareholders, together with investors participating in the concurrent financing, will collectively control approximately 95.25% of the post-merger entity. Current Aethlon stockholders will retain approximately 4.75% ownership in the new company, in addition to receiving contingent value rights connected to the potential future monetization of Aethlon's existing Hemopurifier technology platform.

The ownership structure means the proposed transaction would shift the combined company's primary operating focus toward North Immunology's antibody development programs, while Aethlon stockholders would retain an interest in the new entity and potential future value tied to the Hemopurifier platform.

$180 Million PIPE Financing

Alongside the merger announcement, the companies disclosed an oversubscribed $180 million private investment in public equity (PIPE) financing, indicating robust institutional interest in the transaction. The financing syndicate comprises several prominent healthcare-focused investment firms, including Bain Capital Life Sciences, Janus Henderson Investors, Deep Track Capital, Longitude Capital, Soleus Capital, Invus, Sirenia Capital Management LP, Farallon Capital Management, Adage Capital Partners LP, and TCGX.

The $180 million financing figure incorporates the conversion of roughly $34 million in existing convertible promissory notes held by North Immunology, including accumulated interest, premiums, and associated fees. Management projects that the capital raised will be sufficient to support the combined company's operational requirements through the latter half of 2028.

North Immunology's Development Pipeline

North Immunology specializes in developing bispecific antibody therapeutics that modulate inflammatory signaling pathways associated with immune-mediated conditions. The company's most advanced program, NOR-101, is a half-life extended bispecific antibody that simultaneously targets IL-13 and IL-18, with primary development focused on treating atopic dermatitis.

The initial Phase 1a clinical trial evaluating NOR-101 is slated to commence during the first quarter of 2027, with preliminary pharmacokinetic and safety results anticipated by mid-2027. Management has indicated intentions to launch both Phase 1b and Phase 2b studies examining NOR-101 in atopic dermatitis patients throughout 2027, with primary efficacy and safety data from these expansion studies projected to become available in 2028. These clinical milestones, together with the proposed financing and merger approvals, are the principal developments identified in the announcement's stated timeline.

Closing Timeline and Conditions

The merger transaction is anticipated to reach completion during the first quarter of 2027, subject to obtaining the necessary shareholder votes, regulatory clearances, and stock exchange approval. Upon closing, North Immunology's current executive leadership team and board of directors will assume control of the merged organization. Until those conditions are satisfied, the announced ownership structure, Nasdaq ticker transition, and leadership change remain part of the proposed transaction rather than completed events.

According to TipRanks data, the latest analyst consensus rating on AEMD stock stands at Hold, with a price target of $1.50.

Source: Blockonomi